Rationality of Use and Interaction of Antihyperlipidemic Drugs in Outpatient Care at South Tangerang City General Hospital

Nur Wulan Adi Ismaya; Ida Listiana; Reynaldis Mediatris Ngga'a; Suny Koswara Rahajeng; Fenita Purnama Sari Indah; Tri Okta Ratnaningtyas

Authors

Nur Wulan Adi Ismaya STIKes Widya Dharma Husada Tangerang
Ida Listiana STIKes WIdya Dharma Husada tangerang
Reynaldis Mediatris Ngga'a STIKes WIdya Dharma Husada tangerang
Suny Koswara Rahajeng STIKes WIdya Dharma Husada tangerang
Fenita Purnama Sari Indah STIKes WIdya Dharma Husada tangerang
Tri Okta Ratnaningtyas STIKes Widya Dharma Husada tangerang

Keywords:

antihyperlipidemia drugs, drug interaction, hyperlipidemia, rationale drug use, retrospective study

Abstract

Hyperlipidemia is one of the main risk factors for cardiovascular disease. The use of antihyperlipidemic agents should be rational, and drug interactions can affect the effectiveness of therapy. This study aimed to evaluate the rational use and potential drug interactions of antihyperlipidemic agents in outpatient care at a General Hospital in South Tangerang City in December 2024. This research is descriptive with a retrospective data collection approach. A total sample of 172 prescriptions met the inclusion criteria. The evaluation included the appropriateness of indication, drug, dosage, administration, time interval, patient, and method of administration. The use of antihyperlipidemic agents was 100% appropriate for indication, drug, dosage, administration, and time interval; 100% for the correct patient; and only 80.32% appropriate for the method of administration. Drug interactions occurred in 55.32% of patients, with severity classified as major (57.57%), moderate (37.37%), and minor (5.05%). The most frequent interactions occur between simvastatin and amlodipine. Conclusion: The use of antihyperlipidemic agents in outpatient care at a General Hospital in South Tangerang City is mostly rational; however, drug interactions are still present and need attention to improve therapeutic outcomes.

References

Adiputra, IMS, Trisnadewi, NW, Oktaviani, NPW, & Munthe, SA (2021). Health research methodology.

Attardo, S., Musumeci, O., Velardo, D., & Toscano, A. (2022). Neuromuscular adverse effects of statins. International Journal of Molecular Sciences, 23(15). https://doi.org/10.3390/ijms23158364

Ballena-Caicedo J, dkk. “Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis”

Drugs.com. (nd). Drug interaction checker. Retrieved October 5, 2025, from https://www.drugs.com/drug_interactions.html

Fadilah, H., Indria, DM, & Wibiso, N. (2023). The relationship between polypharmacy and potential drug interactions in patients prescribed antihyperlipidemic drugs. Journal of Complementary Biomedicine, 10(1): 1–13.

Faiqoh, A. (2023). Overview of the use of statins as outpatient hyperlipidemia therapy at Mitra Siaga Hospital, Tegal, 8(1), 1–19.

Hasan, R. (2021). Study of antihyperlipidemic drug interactions in outpatients at Dr. MM Dunda Limboto Regional Hospital. Tinctura Pharmaceutical Journal, 3(1): 15–22. https://doi.org/10.35316/tinctura.v3i1.1610

Lai, A., Kam, K., Tan, G.M., Tam, M., Chi, K., So, K., Chui, K.L., Wu, E.B., Chan, Y.S., & Yan, B. (2024). Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: A population-based study. Cardiovascular Pharmacology – Cardiovascular Pharmacotherapy, 45.

Mahwal, I., Untari, EK, & Nurmainah. (2022). Comparison of statins to side effect events related to myalgia. Journal of Science and Health, 4(2): 147–154.

Muzakkir, A., & Antonius, R. (2025). Fetal Bridging Outcome Gaps in Pregnancy in Dyslipidemia Infected Management Syphilis Treated in Indonesia with Penicillin Through G : A Systematic Europath Strategies Review. Cdk-339, 52(4): 0–3.

Paulina, A., Angin, MP, & Hidayaturahmah, R. (2023). Evaluation of cholesterol medication use in hyperlipidemia patients in the outpatient unit of Mutiara Bunda Hospital. Malahayati Pharmacy Journal, 6(1), 63–75. https://doi.org/10.33024/jfm.v6i1.8199

Pedersen, E., Garcia, B. H., Halvorsen, K. H., Eggen, A. E., Schirmer, H., & Waaseth, M. (2021). Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in Tromsø 7. BMC Cardiovascular Disorders, 21(1), 1–11. https://doi.org/10.1186/s12872-021-01866-1

Perkeni. (2021). Management of dyslipidemia in Indonesia 2021. PB Perkeni.

Perki. (2022). Dyslipidemia management guidelines 2022. http://scioteca.caf.com/bitstream/handle/123456789/1091/RED2017-Eng-8ene.pdf

Refdanita. (2022). Overview of diabetes therapy with comorbid hyperlipidemia in hospitals. Endurance Journal, 6(1), 103–113. https://doi.org/10.22216/jen.v6i1.146

Reyaan, IBM, Kuning, C., & Adnyana, IK (2021). Study of potential drug interactions in polypharmacy prescriptions at two pharmacies in Bandung City. Journal of Pharmaceutical Management and Services, 11(3), 145. https://doi.org/10.22146/jmpf.56931

Rudiartha, I. L. M., & Setiawan, P. Y. B. (2023). Perbaikan Profil Lipid pada Masyarakat Muslim Hiperlipidemia dengan Puasa Ramadhan di Denpasar Selatan. Indonesian Journal of Pharmaceutical Education (e-Journal), 3(3), 2775–3670. https://doi.org/10.37311/ijpe.v3i3.21913

Sari, W., Ifaya, M., & Kadarman, A. (2022). Evaluation of the rationality of the use of antihyperlipidemic drugs at the Bahodopi Community Health Center, Morowali Regency, Central Sulawesi in 2019. Jurnal Pharmacia Mandala Waluya, 1(4), 158–164. https://doi.org/10.54883/jpmw.v1i4.34

Sinaga, TM, Rusip, G., & Fachrial, E. (2024). Study of antihyperlipidemic drug interactions at Royal Prima General Hospital Medan. Journal of Pharmacy, 5.

Stockley, I. H., & Preston, C. L. (Eds.). (2013). Stockley's drug interactions (10th ed.). London, UK: Pharmaceutical Press.